Lumos Diagnostics Holdings Share Price and Company Fundamentals
Last traded: Today at 5:55 AM
Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests. The company develops and manufactures proprietary and in-licensed POC diagnostic tests. Its products include FebriDx, a test that differentiates between bacterial and viral respiratory infections; and CoviDx, an antigen test for COVID-19. The company also develops and manufactures POC diagnostic tests on commercial contract basis, which include POC diagnostic tests, digital reader formats, and digital applications. It offers its products through distributors primarily in the North American and European markets. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
Beta
-
Market cap
$179.43M
Enterprise value
$108.03M
Company profile
| Primary activities | Development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. |
|---|---|
| Industry / Sector | Diagnostics & Research / Healthcare |
| Website | http://lumosdiagnostics.com |
| Mailing address | Level 4 100 Albert Road South Melbourne Melbourne VIC 3205 Australia |
| Phone / Fax | 760-683-5374 / |
| Share registry | COMPUTERSHARE INVESTOR SERVICES PTY LIMITED |
Dividends
Lumos Diagnostics Holdings does not pay dividends.
Company Executives
As of Jul 2021, following are the company executives and directors listed on Lumos Diagnostics Holdings.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Samuel Lanyon | Exec. Chairman | ||
| Dr. Robert P. Sambursky M.D. | CEO & Exec. Director | ||
| Ms. Melanie Jaye Leydin C.A., B.Bus, CA | CFO & Company Sec. | 47 | |
| Mr. Kurt Phinney | VP of Operations | ||
| Dr. Sacha Dopheide Ph.D. | Chief Technology Officer | ||
| Ms. Jill Thompson | Sr. VP of Corp. Strategy & Devel. | ||
| Ms. Sarah Glubka | Sr. Director of HR | ||
| Dr. Jeffrey Bishop | Sr. VP R&D | ||
| Mr. Aaron Erlandson | Sr. VP of Fin. | ||
| Ms. Annie Bell | Sr. Director of Medical Affairs |
Profitability and management effectiveness
Profit margin
-71.64%
Operating margin
-64.85%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Lumos Diagnostics Holdings is 179.43M and its enterprise value is 108.03M. The enterprise value to revenue ratio of LDX is 6.53.
Companies similar to Lumos Diagnostics Holdings (LDX)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Lumos Diagnostics Holdings (ASX:LDX) Frequently Asked Questions
1. What is Lumos Diagnostics Holdings's Stock Symbol?
Lumos Diagnostics Holdings trades on ASX under the ticker symbol "LDX".
2. What is Lumos Diagnostics Holdings's stock price today?
One share of LDX stock can currently be purchased for approximately $1.195.
3. How can I contact Lumos Diagnostics Holdings?
Lumos Diagnostics Holdings's mailing address is Level 4 100 Albert Road South Melbourne Melbourne VIC 3205 Australia. The company can be reached via phone at 760-683-5374.
4. What is Lumos Diagnostics Holdings's official website?
The official website of Lumos Diagnostics Holdings is http://lumosdiagnostics.com.
5. Which share registry manages Lumos Diagnostics Holdings's stock?
Lumos Diagnostics Holdings's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.